Retatrutide – 10mg

Retatrutide: a triple-receptor peptide researched for metabolic and weight regulation benefits.

Introducing Retatrutide.
Following the emergence of Ozempic (semaglutide) and Mounjaro (tirzepatide), Retatrutide has demonstrated even greater weight loss outcomes in clinical studies, setting a new benchmark in research.

Retatrutide represents a synthetic peptide, which research indicates functions as a triple agonist. This compound comprises a 39-amino-acid sequence, engineered as an analog to the gastric inhibitory polypeptide (GIP), with additional affinity observed towards the glucagon-like peptide-1 (GLP-1) receptor and the glucagon (GCG) receptor (1)(2).

Typically, these receptors are engaged by their corresponding hormones GIP, GLP-1, and GCG, which serve as critical regulators within the endocrine system.
It is hypothesized that:

• GLP-1 and GIP, as incretin hormones, may support insulin secretion and promote satiety .

• Glucagon may help raise glucose levels during fasting by potentially raising glucose levels during periods without food intake.

• GLP-1 activation may slow gastric emptying.

• GCG activation could enhance energy expenditure and promote fat metabolism, particularly by influencing liver processes and converting white fat cells to beige fat cells.

The combined action across all three pathways suggests a complex and promising effect on metabolic regulation, particularly relevant to research into glycemic control, energy use, and weight dynamics.

Retatrutide is chemically modified with a C20 moiety, extending its half-life and enabling longer-acting activity in experimental contexts (3).

Product intended for research purposes

Additional informations:

• The product (substance) isn’t a food or diet supplement and is not suitable for human consumption.

• Keep out of children’s reach

• Keep container tightly closed.

• Store in a dry, cool and shaded place; protect from moisture.

• Store only in the original container.

• Avoid contact during pregnancy and breast feeding.

• Consult a doctor in the event of feeling unwell or having adverse effects related to the contact with the substance.

Article & Study Links

Article

https://ukcompounding.com/blogs/news/retatrutide-vs-ozempic-comparison

Study #1: 24% Weight loss on retatrutide

https://jamanetwork.com/journals/jama/article-abstract/2807151

Study #2 Fatty liver disease alleviated by Lilly’s ‘triple-G’ obesity drug in small study

https://www.statnews.com/2023/06/26/eli-lilly-fatty-liver-disease-retatrutide-obesity-drug/

Study #3 Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss

https://www.nejm.org/doi/full/10.1056/NEJMoa2301972?query=featured_home